Navigating Global Regulatory Frameworks: A Review of Submission Frameworks, Approvals and Timelines Across the FDA, EMA and MHRA

Abstract

Launching new pharmaceutical drugs is a complex, multi-phase process involving years of research and development. Regulatory approval is critical for ensuring that medicinal products meet rigorous standards of safety, efficacy, and quality. In the drug development lifecycle, clinical trial and marketing authorisation submissions represent pivotal regulatory milestones in the journey of a drug from research to commercialisation. This review focuses on navigating the regulatory submission frameworks, documentation, and timelines for the approval of clinical trials and marketing authorisation across the FDA, EMA and MHRA. Real-world clinical trials of some drugs have been analysed in this review as case studies, and the regulatory authority decisions have been compared to identify the key requirements for successful clinical trial and marketing authorisation applications. The review reveals that the FDA, EMA and MHRA are regulated globally by the ICH guidelines, specific regional regulations, and similar documentation requirements, but differ in their submission, review processes, approaches to evidence/endpoints, risk tolerance and timelines. The FDA adopts a relatively flexible approach, accepting single-arm trials with surrogate endpoints to support accelerated approval, with subsequent confirmatory studies required to verify clinical benefit. In contrast, the EMA operates a conservative, evidence-based framework that generally favours comparator-controlled trials and robust clinical endpoints, with conditional approvals subject to stringent obligations and annual review. Post-Brexit, the MHRA operates a hybrid model that combines EMA-style conditional approvals and reliance pathways that facilitate the recognition of decisions from other regulatory authorities, thereby increasing both regulatory agility and review efficiency.

Conclusion: Differences in regulatory agency approvals have important implications for global drug development programs, and efforts are underway to harmonise drug approval processes globally.